Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.11 0.33 −9.59%
Market cap
$13.0M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Where the cash went Twelve months to 30 June 2026

Free cash flow was −$38.1M: capital expenditures were more than operating cash flow. Cash fell by $69.2M. Lines the picture does not name came to −$87.3M. What is a cash flow statement?

Free cash flow
−$38.1M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$69.2M over the period
Where the cash went, in billions of dollars
Operating cash flow0.0
Free cash flow0.0
Acquisitions, net+0.1
Into investments, net0.0
Other−0.1
Change in cash−0.1

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
183.19 163.62 183.45 215.65

+8 more TTM periods

Operating Cash Flow
(38.05) (21.38) (4.77) (16.91)
Investing cash flow
56.14 38.45 35.42 88.85
Financing cash flow
(85.94) (85.95) (86.03) (86.01)
Ending Cash
(21.32) (21.33) 47.87 89.15

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026